The results suggested that invalids who have high NUP37 expression might resist to some anti-cancer drugs, such as PF-4708671 and GSK269962A, at the same time have sensitive to most anti-cancer drugs, such as MK-1775 and erlotinib. This evidence concerns the gene NUP37 and cancer.